Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Well-differentiated neuroendocrine tumors (NETs) management has been significantly improved by somatostatin receptor (SSTR) targeted therapies.
• SSTR-targeted imaging and peptide receptor radionuclide therapy (PRRT) represent revolutionary advancements in NET care.

Purpose of the Study:

• To provide a comprehensive review of current SSTR-targeted imaging and PRRT for neuroendocrine tumors.
• To discuss FDA-approved SSTR-agonist PET tracers, predictive imaging biomarkers, and Lu177-DOTATATE PRRT.
• To explore evolving aspects of PRRT, including post-therapy imaging, retreatment, and dosimetry, as well as future research directions.

Main Methods:

• Review of current literature and FDA-approved SSTR-agonist PET tracers.
• Elaboration on Lu177-DOTATATE PRRT, including its application and optimization.
• Discussion of emerging trends in PET imaging, alpha particle therapy, and combination strategies.

Main Results:

• SSTR-targeted PET imaging and Lu177-DOTATATE PRRT are established modalities for NET management.
• Predictive imaging biomarkers and dosimetry show potential for optimizing PRRT outcomes.
• Ongoing research focuses on novel PET tracers, alpha therapies, and combination treatments.

Conclusions:

• SSTR-targeted approaches have revolutionized NET treatment, offering improved diagnostic and therapeutic options.
• Further research into advanced imaging, dosimetry, and novel therapeutic strategies, including alpha particle therapy and combination treatments, holds promise for enhancing patient outcomes in NETs.